Gerardo Ferrer

Dr. Gerardo Ferrer

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Blood
Verified
Journal Article
Closed access
PDF file
Alfons NavarroAlfons Navarro
Alfons Navarro
TDTania Diaz
Tania Diaz
AMAntonio Martinez
Antonio Martinez
AGAnna Gaya
Anna Gaya
APAina Pons
Aina Pons
MMMariano Monzo
Mariano Monzo
The behavior of classic Hodgkin lymphoma (cHL) is determined by both the intrinsic features of the tumor cells and the characteristics of the microenvironment, making the analysis of entire lymph nodes an effective approach to understanding the disease. We examined the influence of our previously reported 25-microRNA signature for cHL on clinical outcome in 89 homogeneously treated cHL patients with a median follow-up of 80 months. Patients with low miR-135a expression had a higher probability of relapse (P = .04) and a shorter disease-free survival (P = .02). Functional analysis of cHL cell lines showed that mature miR-135a levels increased after pre–miR-135a transfection, causing apoptosis and decreased cell growth. Target analysis showed a direct regulation by miR-135a of JAK2, a cytoplasmic tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. miR-135a–mediated JAK2 down-regulation led to decreased mRNA and protein levels of the antiapoptotic gene Bcl-xL, suggesting a role for Bcl-xL in miR-135a/JAK2–mediated apoptosis. Our findings confirm the critical role of miR-135a in the survival of cHL cells and in the prognosis of cHL patients, indicating that novel treatment approaches targeting miR-135a may potentially benefit these patients.

2 December 2010 in Blood
Verified
Journal Article
Closed access
CMCarol Moreno
Carol Moreno
KHKate Hodgson
Kate Hodgson
GFGerardo Ferrer
Gerardo Ferrer
MEMontse Elena
Montse Elena
Xavier FilellaXavier Filella
Xavier Filella
EMEmili Montserrat
Emili Montserrat
We analyzed prevalence, characteristics, clinical correlates, and prognostic significance of autoimmune cytopenia in patients with chronic lymphocytic leukemia. Seventy of 960 unselected patients (7%) had autoimmune cytopenia, of whom 19 were detected at diagnosis, 3 before diagnosis, and 48 during the course of the disease. Forty-nine patients had autoimmune hemolytic anemia, 20 had immune thrombocytopenic purpura, and 1 had both conditions. A clear association was observed between autoimmune cytopenia and poor prognostic variables (ie, high blood lymphocyte count, rapid blood lymphocyte doubling time, increased serum β-2 microglobulin level, and high expression of ζ-associated protein 70 and CD38). Nevertheless, the outcome of patients with autoimmune cytopenia as a whole was not significantly different from that of patients without this complication. Furthermore, no differences were observed according to time at which cytopenia was detected (ie, at diagnosis, during course of disease). Importantly, patients with advanced (Binet stage C) disease because of an autoimmune mechanism had a significantly better survival than patients in advanced stage related to a massive bone marrow infiltration (median survivals: 7.4 years vs 3.7 years; P = .02). These results emphasize the importance of determining the origin of cytopenia in patients with chronic lymphocytic leukemia for both treatment and prognostic purposes.

17 January 2011 in Haematologica
Verified
Journal Article
Closed access
KHK. Hodgson
K. Hodgson
GFGerardo Ferrer
Gerardo Ferrer
EME. Montserrat
E. Montserrat
CMC. Moreno
C. Moreno
Chronic lymphocytic leukemia is frequently associated with immune disturbances. The relationship between chronic lymphocytic leukemia and autoimmune cytopenias, particularly autoimmune hemolytic anemia and immune thrombocytopenia, is well established. The responsible mechanisms, particularly the role of leukemic cells in orchestrating the production of polyclonal autoantibodies, are increasingly well understood. Recent studies show that autoimmune cytopenia is not necessarily associated with poor prognosis. On the contrary, patients with anemia or thrombocytopenia due to immune mechanisms have a better outcome than those in whom these features are due to bone marrow infiltration by the disease. Moreover, fears about the risk of autoimmune hemolysis following single agent fludarabine may no longer be appropriate in the age of chemo-immunotherapy regimens. However, treatment of patients with active hemolysis may pose important problems needing an individualized and clinically sound approach. The concept that autoimmune cytopenia may precede the leukemia should be revisited in the light of recent data showing that autoimmune cytopenia may be observed in monoclonal B-cell lymphocytosis, a condition that can only be detected by using sensitive flow cytometry techniques. On the other hand, there is no evidence of an increased risk of non-hemic autoimmune disorders in chronic lymphocytic leukemia. Likewise, there is no epidemiological proof of an increased risk of chronic lymphocytic leukemia in patients with non-hemic autoimmunity. Finally, since immune disorders are an important part of chronic lymphocytic leukemia, studies aimed at revealing the mechanisms linking the neoplastic and the immune components of the disease should help our understanding of this form of leukemia.

1 April 2008 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
AGAmir J. Guri
Amir J. Guri
RHRaquel Hontecillas
Raquel Hontecillas
GFGerardo Ferrer
Gerardo Ferrer
OCOriol Casagran
Oriol Casagran
UWUmesh Wankhade
Umesh Wankhade
JBJosep Bassaganya-Riera
Josep Bassaganya-Riera

1 May 2011 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
KHKate Hodgson
Kate Hodgson
GFGerardo Ferrer
Gerardo Ferrer
APArturo Pereira
Arturo Pereira
CMCarol Moreno
Carol Moreno
EMEmili Montserrat
Emili Montserrat

14 September 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
SVStefano Vergani
Stefano Vergani
IKIlya Korsunsky
Ilya Korsunsky
AMAndrea Nicola Mazzarello
Andrea Nicola Mazzarello
GFGerardo Ferrer
Gerardo Ferrer
NCNicholas Chiorazzi
Nicholas Chiorazzi
DBDavide Bagnara
Davide Bagnara
Efficient and accurate high-throughput DNA sequencing of the adaptive immune receptor repertoire (AIRR) is necessary to study immune diversity in healthy subjects and disease-related conditions. The high complexity and diversity of the AIRR coupled with the limited amount of starting material which can compromise identification of the full biological diversity makes such sequencing particularly challenging. AIRR sequencing protocols often fail to fully capture the sampled AIRR diversity, especially for samples containing restricted numbers of B lymphocytes. Here, we describe a library preparation method for immunoglobulin sequencing that results in an exhaustive full-length repertoire where virtually every sampled B-cell is sequenced. This maximizes the likelihood of identifying and quantifying the entire IGHV-D-J repertoire of a sample, including the detection of rearrangements present in only one cell in the starting population. The methodology establishes the importance of circumventing genetic material dilution in the pre-amplification phases and incorporates the use of certain described concepts: 1) balancing the starting material amount and depth of sequencing, 2) avoiding IGHV gene specific amplification, and 3) using Unique Molecular Identifier. Together, this methodology is highly efficient, in particular for detecting rare rearrangements in the sampled population and when only a limited amount of starting material is available.